DOCSLIB.ORG

Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes Clinical Care/Education/Nutrition/Psychosocial Research ORIGINALDiabetes ARTICLE Care Publish Ahead of Print, published online February 19, 2011 Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes 1 2 TADEJ BATTELINO, MD, PHD REVITAL NIMRI, MD especially useful in patients with hypogly- 2 3 MOSHE PHILLIP, MD PER OSKARSSON, MD, PHD 1 3 cemia unawareness and/or frequent epi- NATASA BRATINA, MD, PHD JAN BOLINDER, MD, PHD sodes of hypoglycemia (18). However, the hypoglycemia preventive effect of con- tinuous glucose monitoring has not been — OBJECTIVE To assess the impact of continuous glucose monitoring on hypoglycemia in established. Therefore, we designed a ran- people with type 1 diabetes. domized, controlled, multicenter clinical RESEARCH DESIGN AND METHODS—In this randomized, controlled, multicenter trial to evaluate the effect of continuous study, 120 children and adults on intensive therapy for type 1 diabetes and a screening level of glucose monitoring on hypoglycemia in glycated HbA1c ,7.5% were randomly assigned to a control group performing conventional children and adults with type 1 diabetes. home monitoring with a blood glucose meter and wearing a masked continuous glucose monitor every second week for five days or to a group with real-time continuous glucose monitoring. The primary outcome was the time spent in hypoglycemia (interstitial glucose concentration ,63 RESEARCH DESIGN AND mg/dL) over a period of 26 weeks. Analysis was by intention to treat for all randomized patients. METHODS RESULTS—The time per day spent in hypoglycemia was significantly shorter in the contin- uous monitoring group than in the control group (mean 6 SD 0.48 6 0.57 and 0.97 6 1.55 Patients Patients aged between 10 and 65 years h/day, respectively; ratio of means 0.49; 95% CI 0.26–0.76; P = 0.03). HbA1c at 26 weeks was lower in the continuous monitoring group than in the control group (difference 20.27%; 95% with type 1 diabetes diagnosed for more CI 20.47 to 20.07; P = 0.008). Time spent in 70 to 180 mg/dL normoglycemia was significantly than 1 year, with reasonable metabolic longer in the continuous glucose monitoring group compared with the control group (mean control assessing carbohydrate intake and P hours per day, 17.6 vs. 16.0, =0.009). self-adjusting insulin, and a HbA1c level , — 7.5%, using intensive insulin treatment CONCLUSIONS Continuous glucose monitoring was associated with reduced time spent with either an insulin pump or multiple in hypoglycemia and a concomitant decrease in HbA1c in children and adults with type 1 di- abetes. daily injections, and not using a real-time continuous glucose monitoring device for at least 4 weeks were eligible for the study. All eligible patients identified from the local diabetes registries were invited to he benefits of intensive treatment of reduced adherence to therapeutic deci- participate and screened consecutively type 1 diabetes, established almost sions (10). Finally, hypoglycemia may T fi based on the order of their positive reply. 20 years ago (1), are dif cult to ach- be associated with permanent damage The study protocol was designed by ieve, despite the increased use of insulin to the central nervous system (CNS) the researchers and approved by the in- analogs and insulin pumps, with only a (11) and may permanently influence cog- stitutional or national medical ethics minority of patients maintaining their gly- nitive functions in children (12) but not committees from all three centers, and cated HbA within the target range (2). in adults (13). 1c the conduct of the study was consistent Intensive insulin treatment and lower Recently, devices for real-time con- with the Good Clinical Practice provi- HbA increase exposure to hypoglyce- tinuous glucose monitoring have been 1c sions of the Declaration of Helsinki with mia (3,4). The risk of hypoglycemia is introduced to aid self-management of all amendments and local regulatory re- even higher in children and adolescents glycemic control and have been shown quirements. A written informed consent (5,6) and increases with the duration of to improve HbA levels in people with 1c was obtained from all participants and pa- diabetes (7). Frequent hypoglycemia is type 1 diabetes (14–17). In clinical practice rents of minors (under 18 years of age, associated with hypoglycemia unaware- recommendations, it has also been sugges- who signed an assent) before enrollment. ness (8,9), which may in turn lead to ted that continuous glucose monitoring is At screening patients provided a ccccccccccccccccccccccccccccccccccccccccccccccccc blood sample for measurement of HbA1c From the 1Department of Pediatric Endocrinology, Diabetes and Metabolism, UMC-University Children’s and entered a 4-week run-in period dur- Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; the 2The Jesse Z and Sara Lea ing which self-monitoring of blood glu- Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider cose (SMBG) was conducted according Children’s Medical Center, Petah Tikva and Sackler Faculty of Medicine, Tel-Aviv University, Israel; and the ’ 3 to patients standard glycemic manage- Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, ment regimen. A FreeStyle blood glucose Sweden. Corresponding author: Tadej Battelino, [email protected]. meter (Abbott Diabetes Care, Alameda, Received 20 October 2010 and accepted 13 January 2011. CA) was provided to familiarize patients DOI: 10.2337/dc10-1989. Clinical trial reg. no. NCT00843609, clinicaltrials.gov. with FreeStyle test strips and collect base- This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10. line SMBG frequency and glucose levels. 2337/dc10-1989/-/DC1. © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly Diaries were distributed for recording cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ events of hypoglycemia and associated licenses/by-nc-nd/3.0/ for details. food intake, insulin doses, and exercise. care.diabetesjournals.org DIABETES CARE 1 Copyright American Diabetes Association, Inc., 2011 Continuous glucose monitored in type 1 diabetes All patients meeting the eligibility criteria, events, and serious adverse events regard- including all data collected for patients including HbA1c result from the screening less of cause, were reviewed and reported. that discontinued prematurely. An excur- visit, were invited to attend the randomi- Diabetes self-management was ad- sion was defined as all consecutive re- zation visit. justed by patients based on the blood cordings outside the boundary covering glucose measurements in the control at least 10 min. The duration of an group and blood glucose measurements excursion was defined as the elapsed Study design and continuous glucose data in the con- time from first excursion to the first Following the 1-month run-in period, tinuous glucose monitoring group. Sam- reading indicating return inside the ex- patients were randomized to participate ples for HbA1c were collected at days 1, cursion boundary. Continuous glucose in a 6-month intervention period. Pa- 60, and 180. All samples for HbA1c were monitoring data in both groups were used tients were assigned to home monitoring sent to a central laboratory (LKF, Kiel, to estimate the amount of time per day the with a FreeStyle blood glucose meter Germany; measurement by Bio-Rad Vari- glucose level was hypoglycemic (,63 and a masked continuous glucose moni- ant II Turbo analyzer, Bio-Rad Laborato- mg/dL, ,70 mg/dL, or ,55 mg/dL), hyper- tor to be worn for 5 days every second ries, Hercules, CA). glycemic (.180 mg/dL or .250 mg/dL), week (control group) or to a group with and in the target range (70 to 180 mg/dL real-time continuous glucose monitoring, Statistical analysis or 90 to 180 mg/dL) for each patient. The wearing individual sensors for 5 days The primary outcome was time spent in number of hypoglycemic excursions (,55 continuously for 26 weeks (continuous hypoglycemia (,63 mg/dL) during the and ,63 mg/dL) per day and separately monitoring group). Patients and investi- 26-week study period. A sample size of during the night period of 0000–0600 h gators were masked for the continuous 120 patients was planned to have a power was also calculated. The risk associated glucose monitoring data in the control of 80% to detect a difference in the time with glucose concentration outside the group. Patients were allocated to either spent in hypoglycemia between study recommended range was assessed by cal- group by permuted block randomization groups, assuming a population difference culating low blood glucose indexes (LBGI) stratified according to age (10 to 17 years of 42%, a SD of 1.12, an a-level of 0.05, andhighbloodglucoseindexes(HBGI) pediatric, 18 to 65 years adult) and study and a loss to follow-up of no more than 17%. (20). Comparisons between study groups center. The randomization sequence was All analyses were performed accord- were performed with the use of the Mann- computer generated, and allocations were ing to the intent-to-treat (ITT) principle, Whitney U test. Confidence intervals for concealed using envelopes. Both groups were provided with the FreeStyle Navi- gator (Abbott Diabetes Care), a continu- Table 1—Baseline characteristics of the patients ous glucose monitoring system that measures glucose in interstitial fluid. All patients were trained to insert and Control Continuous calibrate subcutaneous sensors and to Group Monitoring Group operate the continuous monitoring de- N 58 62 vice. Patients in the continuous monitor- Female sex, number (%) 19 (33) 26 (42) ing group were instructed in the use of Age (years)* 26.0 6 14.6 25.7 6 14.1 real-time glucose readings; however, no Pediatric, number (%) 26 (45) 27 (44) written guidelines were given on adjust- BMI (kg/m2)* 22.0 6 3.8 22.4 6 3.8 ment of diabetes management based on Duration of diabetes (years)* 11.4 6 11.4 11.6 6 11.3 the real-time readings.
Load more

Recommended publications
  • Blood Glucose Monitoring in Type 1 Diabetes (Adults)
    FACTSHEET | JUNE 2021 Blood Glucose Monitoring in type 1 diabetes (adults) RSS Diabetes Service Blood glucose goes up and down during the day depending on carbohydrate intake, physical activity, insulin doses, wellbeing and stressors. Blood glucose results tend to be lower before meals and higher after meals. Blood glucose monitoring guides your self-care. The first step in blood glucose monitoring is knowing your blood glucose target ranges. What are the recommended blood glucose (BG) targets For most people with type 1 diabetes, it is recommended that blood glucose be as close to normal as possible to reduce the risk of long term complications. In general, recommended blood glucose targets are: Time Target BG Fasting and before meals 4.0 – 8.0mmol/L 2 hours after meals 4.0 – 10.0mmol/L However, for some people (e.g. infants and young children, the aged, those with impaired hypoglycaemia awareness or other health conditions), blood glucose targets will need to be set higher. If you are pregnant or trying to get pregnant, your blood glucose targets will be set lower. When should I test my blood glucose (BG)? Your blood glucose levels will indicate if your diabetes is well managed or if changes are needed. Blood glucose results overnight or before breakfast tell you how well your diabetes is controlled overnight by the basal insulin. Blood glucose results before lunch, before the evening meal and at bedtime tell you if your meal time rapid acting insulin doses are correct. Extra tests are recommended if you: • feel unwell, as part of your sick day action plan • are planning some physical activity, during and after physical activity • are using machinery • are about to drive • are concerned about unstable, unexpected or unexplainable results.
    [Show full text]
  • Blood Glucose Monitoring
    Blood Glucose Monitoring Many people are frightened to check their blood sugar levels because they do not want to see levels that are higher or lower than their target range. However, checking your blood sugars puts you in control of your diabetes. Remember, your blood sugar levels are what they are whether you know about them or not but when you know what they are; you can make adjustments, if needed. Monitoring your blood sugar levels is the most accurate way of you seeing the effectiveness of your lifestyle changes and medications. Monitoring provides you with the ability to identify possible causes of blood sugar fluctuations. Tips for Monitoring • Wash your hands with soap in warm water before checking your blood sugar • Ensure your test strips have not expired • Remember to calibrate your meter (if your meter requires this) • Use the sides of your fingers and remember to use different fingers o Do not use alternate site testing if you think your blood sugar is very high or low – finger checks give you the most accurate result • Discuss the with your healthcare team the best times to check your blood sugar level – which may include: o Prior to your meal and / or 2 hours after the meal o Overnight o If you feel unwell • Record your results in a logbook; this will help you to identify patterns in your levels and make the required changes to get your blood sugar back to your target range; bring your blood sugar records and meter(s) to your healthcare visit - it will help you and your healthcare team to determine your diabetes management needs.
    [Show full text]
  • Flash Glucose Monitoring
    Flash Glucose Monitoring Flash glucose monitoring is a method of glucose testing that measures, displays, and continuously stores glucose readings that are recorded automatically. It can be used by adults to make diabetes treatment decisions, including insulin dosing, without obtaining a blood sample from the fingertip (finger prick). This has the potential to improve blood sugar control and quality of life for people with type 1 or type 2 diabetes, resulting in physical, social, and emotional benefits. A flash glucose monitoring system uses an externally- touchscreen reader device, it transmits the real- worn glucose sensor with a small filament inserted time glucose reading and information on the most under the skin of a person’s upper arm. When recent 8-hour trend to the reader. If the person with the sensor is “flashed” or scanned with a separate diabetes performs at least 3 sensor scans per day diabetes.ca 1-800-BANTING (226-8464) at approximately 8-hour intervals, the flash glucose monitor can record 24-hour glucose profiles. A sensor can be worn continuously for up to 14 days. Blood glucose monitoring gives people living with diabetes a more complete picture of their glucose control, which can lead to better short and long-term treatment decisions and health outcomes. It can help them identify when their blood sugar is trending down, which allows for appropriate and timely action to be taken to avoid hypoglycemia (low blood sugar). It can also provide early indication of hyperglycemia (high blood sugar) over the course of the day and prompt adjustments to medications, activity, and food intake to help achieve blood sugar targets.
    [Show full text]
  • Diabetic Testing
    PRE -ASSESSMENT Diabetic Testing Before CCOHTA decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they are not CCOHTA extensive, systematic reviews of the literature. They are provided here as a quick guide to important, No. 34 current assessment information on this topic. Readers are cautioned that the pre-assessments have May 2004 not been externally peer reviewed. Introduction Diabetes is prevalent in 5% of the Canadian population.1 Type 2 non-insulin dependent diabetes mellitus (NIDDM) accounts for 85% to 90% of patients with diabetes mellitus. Patients with diabetes have an increased risk for developing complications from cardiovascular (i.e., heart, cerebrovascular and peripheral vascular) disease including neuropathy (leading to limb amputation), retinopathy (leading to blindness) and nephropathy (leading to dialysis and transplant). The clinical management of diabetes ranges from surveillance and primary prevention (preventing disease occurrence) to secondary prevention and management of complications. Regular treatment and the measurement of blood lipid parameters, blood pressure and glycemia used to modify treatment plans are encouraged in patients with type 1 (insulin-dependent) or type 2 diabetes (Figure 1).1 Figure 1: Diagnosis and care of diabetes based on glycemic control Management of Diabetes Treating:Treating 1. What is the evidence that LifestyleEducation –about physical improved glycemic control nutritional,lifestyle, nutrition and and delays or leads to fewer disease knowledge complications education Diagnosis and and screening screening AntihyperglycemicAntihyperglycemic medications Glycemic Complications Type 1 control Type 1 or death or typetype 2 2 diabetes diabetes Testing:Testing GlucoseFasting in bloodplasma or plasmaglucose Fructosamine 2.
    [Show full text]
  • Clinical Usefulness of the Measurement of Serum Fructosamine in Childhood Diabetes Mellitus
    Original article http://dx.doi.org/10.6065/apem.2015.20.1.21 Ann Pediatr Endocrinol Metab 2015;20:21-26 Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus Dong Soo Kang, MD1, Purpose: Glycosylated hemoglobin (HbA1c) is often used as an indicator of glucose Jiyun Park, MD1, control. It usually reflects the average glucose levels over two to three months, and Jae Kyung Kim, PhD2, is correlated with the development of long-term diabetic complications. However, Jeesuk Yu, MD, PhD1 it can vary in cases of hemoglobinopathy or an altered red blood cell lifespan. The serum fructosamine levels reflect the mean glucose levels over two to three weeks. 1 This study was designed to determine the clinical usefulness of the combined Departments of Pediatrics and 2Laboratory Medicine, Dankook measurement of serum fructosamine and HbA1c in the management of childhood University Hospital, Dankook diabetes mellitus and the correlation between them. University College of Medicine, Methods: Clinical data on 74 Korean children and adolescents with diabetes Cheonan, Korea mellitus who were under management at the Department of Pediatrics of Dankook University Hospital were evaluated. Their fructosamine and HbA1c levels were reviewed based on clinical information, and analyzed using IBM SPSS Statistics ver. 21. Results: Their HbA1c levels showed a strong correlation with their fructosamine levels (r=0.868, P<0.001). The fructosamine level was useful for the prompt evaluation of the recent therapeutic efficacy after the change in therapeutic modality. It was also profitable in determining the initial therapeutics and for the estimation of the onset of the disease, such as fulminant diabetes.
    [Show full text]
  • Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes
    UnitedHealthcare® Commercial Medical Policy Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes Policy Number: 2021T0347GG Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Durable Medical Equipment, Orthotics, Medical Documentation Requirements ...................................................... 2 Supplies and Repairs/Replacements Applicable Codes .......................................................................... 2 Description of Services ................................................................. 6 Community Plan Policy Benefit Considerations .................................................................. 7 • Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes Clinical Evidence ........................................................................... 7 U.S. Food and Drug Administration ........................................... 13 Medicare Advantage Coverage Summary References ................................................................................... 14 • Diabetes Management, Equipment and Supplies Policy History/Revision Information ........................................... 16 Instructions for Use ..................................................................... 16 Coverage Rationale See Benefit Considerations Insulin Delivery External insulin pumps that deliver insulin by continuous subcutaneous infusion are
    [Show full text]
  • Type 2 Diabetes Screening and Treatment Guideline | Kaiser
    Type 2 Diabetes Screening and Treatment Guideline Interim Update September 2021 .................................................................................................................. 2 Changes as of March 2021 .......................................................................................................................... 2 Prevention .................................................................................................................................................... 2 Screening and Tests .................................................................................................................................... 2 Diagnosis...................................................................................................................................................... 3 Treatment ..................................................................................................................................................... 4 Risk-reduction goals ................................................................................................................................ 4 Lifestyle modifications and non-pharmacologic options ......................................................................... 4 Bariatric surgery ...................................................................................................................................... 5 Pharmacologic options for glucose control ............................................................................................
    [Show full text]
  • (Hba1c) in the Diagnosis of Diabetes Mellitus
    WHO/NMH/CHP/CPM/11.1 Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus Abbreviated Report of a WHO Consultation © World Health Organization 2011 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected] ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.
    [Show full text]
  • Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients with Type 2 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients With Type 2 Diabetes MAUREEN I. HARRIS, PHD, MPH glucose level, measured as HbA1c, and the frequency of self-monitoring in a nation- wide sample of patients with type 2 dia- betes. OBJECTIVE — The aim of the study was to investigate the relationship between blood glu- RESEARCH DESIGN AND cose level, measured as HbA1c, and frequency of self-monitoring in patients with type 2 diabetes. METHODS — Data were analyzed Daily self-monitoring is believed to be important for patients treated with insulin or oral agents from the third National Health and Nutri- to detect asymptomatic hypoglycemia and to guide patient and provider behavior toward reach- tion Examination Survey (NHANES III), ing blood glucose goals. in which questionnaire, clinical, and lab- RESEARCH DESIGN AND METHODS — A national sample of patients with type 2 oratory data were obtained for a repre- diabetes was studied in the third National Health and Nutrition Examination Survey. Data on sentative sample of adults with type 2 therapy for diabetes, frequency of self-monitoring of blood glucose, and HbA1c values were diabetes. NHANES III was conducted obtained by structured questionnaires and by clinical and laboratory assessments. from September 1988 to October 1994 and included a stratified probability sam- RESULTS — According to the data, 29% of patients treated with insulin, 65% treated with ple of the civilian noninstitutionalized oral agents, and 80% treated with diet alone had never monitored their blood glucose or U.S. population (2). Participants were in- monitored it less than once per month.
    [Show full text]
  • Forecasting of Glucose Levels and Hypoglycemic Events
    sensors Article Forecasting of Glucose Levels and Hypoglycemic Events: Head-to-Head Comparison of Linear and Nonlinear Data-Driven Algorithms Based on Continuous Glucose Monitoring Data Only Francesco Prendin, Simone Del Favero * , Martina Vettoretti, Giovanni Sparacino and Andrea Facchinetti Department of Information Engineering, University of Padova, 35131 Padova, Italy; [email protected] (F.P.); [email protected] (M.V.); [email protected] (G.S.); [email protected] (A.F.) * Correspondence: [email protected] Abstract: In type 1 diabetes management, the availability of algorithms capable of accurately forecasting future blood glucose (BG) concentrations and hypoglycemic episodes could enable proactive therapeutic actions, e.g., the consumption of carbohydrates to mitigate, or even avoid, an impending critical event. The only input of this kind of algorithm is often continuous glucose monitoring (CGM) sensor data, because other signals (such as injected insulin, ingested carbs, and physical activity) are frequently unavailable. Several predictive algorithms fed by CGM data only have been proposed in the literature, but they were assessed using datasets originated by different Citation: Prendin, F.; Del Favero, S.; experimental protocols, making a comparison of their relative merits difficult. The aim of the Vettoretti, M.; Sparacino, G.; present work was to perform a head-to-head comparison of thirty different linear and nonlinear Facchinetti, A. Forecasting of Glucose predictive algorithms using the same dataset, given
    [Show full text]
  • Blood Glucose Self-Monitoring in Type 1 and Type 2 Diabetes: Reaching a Multidisciplinary Consensus
    5.p8-16_Consensus.sbg 6/4/04 10:53 am Page 1 Consensus Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus ARTICLE POINTS David Owens, Anthony H Barnett, John Pickup, David Kerr, Phyllis The provision of Bushby, Debbie Hicks, Roger Gadsby and Brian Frier 1home blood glucose monitoring materials is Introduction key to empowerment and In the light of evidence that emerged from the UKPDS (1998) and the delivery of good the DCCT (1993), individual patients must be made aware of the glycaemic control safely. importance of blood glucose monitoring. A multidisciplinary group of healthcare professionals met to discuss blood glucose self-monitoring The NSF for 2Diabetes outlined in type 1 and type 2 diabetes. This article outlines the consensus that the importance of they reached and provides a general basis upon which individual regular monitoring patient care plans may be formulated. Advice is given on home blood of HbA1c levels. glucose monitoring systems for people with different regimens for type 1 and type 2 diabetes. General 3recommendations and specific n the UK in 2001, approximately £90 with suitable training (National Diabetes considerations million was spent on blood glucose Support Team, 2003). are given for blood Itesting strips for people with The recently published NSF for glucose monitoring in diabetes (National Prescribing Centre, Diabetes (England and Wales) type 1 diabetes and 2002). This amount is estimated to be recommends that diabetes services type 2 diabetes. 40% more than the amount spent on oral should be: agents to lower blood glucose levels The article concludes (Tiley, 2002).
    [Show full text]
  • Continuous Glucose Monitoring Roadmap for 21St Century Diabetes Therapy
    Reviews/Commentaries/ADA Statements REVIEW ARTICLE Continuous Glucose Monitoring Roadmap for 21st century diabetes therapy DAVID C. KLONOFF, MD, FACP toring System Gold (CGMS Gold; Medtronic MiniMed, Northridge, CA) (1), the GlucoWatch G2 Biographer (GW2B; Cygnus, Redwood City, CA) (2), ontinuous glucose monitoring pro- era, on the other hand, takes multiple, the Guardian Telemetered Glucose Mon- vides maximal information about poorly focused frames; displays a sequen- itoring System (Medtronic MiniMed) (3), C shifting blood glucose levels tial array of frames whose trend predicts the GlucoDay (A. Menarini Diagnostics, throughout the day and facilitates the the future; produces too much informa- Florence, Italy) (4), and the Pendra (Pen- making of optimal treatment decisions for tion for each frame to be studied carefully; dragon Medical, Zurich, Switzerland) (5). the diabetic patient. This report discusses and operates automatically after it is A sixth monitor, whose premarket ap- continuous glucose monitoring in terms turned on. The two types of blood glucose proval application has been submitted to of its purposes, technologies, target pop- monitors differ in much the same way: 1) the FDA, is the FreeStyle Navigator Con- ulations, accuracy, clinical indications, an intermittent blood glucose monitor tinuous Glucose Monitor (Abbott Labora- outcomes, and problems. In this context, measures discrete glucose levels ex- tories, Alameda, CA) (6). the medical literature on continuous glu- tremely accurately, whereas a continuous The currently
    [Show full text]